Loading
177Lu-PSMA-I&T is a second PSMA radioligand, chemically different from Pluvicto, that has passed two phase 3 trials on progression but has not yet shown a survival benefit.
SPLASH (Lantheus PNT2002, ESMO 2024): rPFS 9.5 vs 6.0 months (HR 0.71) vs ARPI switch in taxane-naive mCRPC; interim OS HR 1.11 (immature, crossover). ECLIPSE (Curium, 7.4 GBq × 6): met rPFS endpoint vs ARPI in the same setting; OS maturing; FDA submission plan pending. Curium's Japanese registrational trial with PeptiDream started February 2026. Widely used off-protocol in Germany and Australia.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Urea-based PSMA ligand with DOTAGA chelator carrying 177Lu; beta emission. Connects to PSMA.
1.177Lu-PSMA-I&T binds PSMA on the cancer cell or is taken up by it.
Compare all products across the US, EU, UK, Japan, China and Australia →
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"177Lu-PSMA-I&T" OR ABSTRACT:"177Lu-PSMA-I&T" OR TITLE:"PNT2002 Lantheus" OR ABSTRACT:"PNT2002 Lantheus" OR TITLE:"Curium 177Lu-PSMA-I&T" OR ABSTRACT:"Curium 177Lu-PSMA-I&T") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about 177Lu-PSMA-I&T, not a curated reading list.
Shares PSMA expression by PET (PSMA-positive), PSMA, PSMA PET, Radioligand therapy (beta emitters).
Shares Curium, Lantheus, PSMA expression by PET (PSMA-positive), PSMA.
Shares PSMA expression by PET (PSMA-positive), PSMA, PSMA PET, Radioligand therapy (beta emitters).
Shares PSMA expression by PET (PSMA-positive), PSMA, PSMA PET, Radioligand therapy (beta emitters).
Shares Curium, Lantheus, Research reactors for medical isotopes (Mo-99, Lu-177, I-131), PSMA PET.
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares PSMA expression by PET (PSMA-positive), PSMA, PSMA PET, Prostate cancer.
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.